FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360607739> ?p ?o ?g. }

• W4360607739 abstract "You have accessJournal of UrologyCME1 Apr 2023MP17-03 THE 17-GENE GENOMIC PROSTATE SCORE® ASSAY IS PROGNOSTIC FOR BIOCHEMICAL FAILURE IN MEN WITH LOCALIZED PROSTATE CANCER AFTER RADIATION THERAPY AT A COMMUNITY CANCER CENTER Daniel Canter, Caroline Branch, Joao Zambon, Jack Groskopf, Aimee Foreman, Amy Lehman, Varun Sama, David Edwards, and John Abran Daniel CanterDaniel Canter More articles by this author , Caroline BranchCaroline Branch More articles by this author , Joao ZambonJoao Zambon More articles by this author , Jack GroskopfJack Groskopf More articles by this author , Aimee ForemanAimee Foreman More articles by this author , Amy LehmanAmy Lehman More articles by this author , Varun SamaVarun Sama More articles by this author , David EdwardsDavid Edwards More articles by this author , and John AbranJohn Abran More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003237.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Genomic assays, which measure and evaluate biological characteristics from tumor biopsies, can more accurately stratify prostate cancer patients beyond conventional risk categories before definitive treatment. For higher-risk patients, a genomic assay is a valuable tool that can improve the decision- making for multimodal duration therapy. To assess the association between the Oncotype DX Genomic Prostate Score® (GPS™) assay and long-term outcomes in men with localized prostate cancer (PCa) after radiation therapy (RT). We hypothesized that the GPS assay is prognostic for biochemical failure (BCF), along with distant metastasis (DM) and PCa-related death (PCD) in PCa patients receiving RT. METHODS: We retrospectively studied men with localized PCa treated with definitive RT from 2010 to 2016. The primary objective was to assess the association between GPS results and time to BCF per the Phoenix criteria; we also evaluated time to DM and PCD. We used Cox proportional hazards regression models for all analyses, with clinicopathologic covariates determined a priori for multivariable modeling. RESULTS: A total of 450 patients (median age=65 years; 35% African American) met the eligibility criteria. There was a strong univariable association between GPS result and time to BCF (hazard ratio [HR] per 20-unit increase=3.08; 95% CI: 2.11-4.46; p<0.001) (Table 1), which persisted after adjusting for clinicopathologic characteristics in multivariable analyses. We also observed this association for time to DM (HR=5.19; 95% CI: 3.06-8.77; p<0.001) (Table 2) and PCD (HR=13.07, 95% CI: 4.42-49.39, p<0.001). Race was not a predictor of time to BCF or DM, and the GPS assay was strongly prognostic for all endpoints in African American and White patients. CONCLUSIONS: In a community-based cohort, the GPS assay was strongly prognostic for time to BCF as well as long-term outcomes in men given RT for localized prostate cancer. Source of Funding: Exact Sciences Corporation © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e213 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Daniel Canter More articles by this author Caroline Branch More articles by this author Joao Zambon More articles by this author Jack Groskopf More articles by this author Aimee Foreman More articles by this author Amy Lehman More articles by this author Varun Sama More articles by this author David Edwards More articles by this author John Abran More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W4360607739 created "2023-03-24" @default.
• W4360607739 creator A5002796515 @default.
• W4360607739 creator A5004776812 @default.
• W4360607739 creator A5006253852 @default.
• W4360607739 creator A5056252192 @default.
• W4360607739 creator A5068617198 @default.
• W4360607739 creator A5068860841 @default.
• W4360607739 creator A5069522440 @default.
• W4360607739 creator A5086658498 @default.
• W4360607739 creator A5091549809 @default.
• W4360607739 date "2023-04-01" @default.
• W4360607739 modified "2023-09-28" @default.
• W4360607739 title "MP17-03 THE 17-GENE GENOMIC PROSTATE SCORE ^® ASSAY IS PROGNOSTIC FOR BIOCHEMICAL FAILURE IN MEN WITH LOCALIZED PROSTATE CANCER AFTER RADIATION THERAPY AT A COMMUNITY CANCER CENTER" @default.
• W4360607739 doi "https://doi.org/10.1097/ju.0000000000003237.03" @default.
• W4360607739 hasPublicationYear "2023" @default.
• W4360607739 type Work @default.
• W4360607739 citedByCount "0" @default.
• W4360607739 crossrefType "journal-article" @default.
• W4360607739 hasAuthorship W4360607739A5002796515 @default.
• W4360607739 hasAuthorship W4360607739A5004776812 @default.
• W4360607739 hasAuthorship W4360607739A5006253852 @default.
• W4360607739 hasAuthorship W4360607739A5056252192 @default.
• W4360607739 hasAuthorship W4360607739A5068617198 @default.
• W4360607739 hasAuthorship W4360607739A5068860841 @default.
• W4360607739 hasAuthorship W4360607739A5069522440 @default.
• W4360607739 hasAuthorship W4360607739A5086658498 @default.
• W4360607739 hasAuthorship W4360607739A5091549809 @default.
• W4360607739 hasConcept C121608353 @default.
• W4360607739 hasConcept C126322002 @default.
• W4360607739 hasConcept C143998085 @default.
• W4360607739 hasConcept C2776235491 @default.
• W4360607739 hasConcept C2779013556 @default.
• W4360607739 hasConcept C2780192828 @default.
• W4360607739 hasConcept C29456083 @default.
• W4360607739 hasConcept C509974204 @default.
• W4360607739 hasConcept C71924100 @default.
• W4360607739 hasConceptScore W4360607739C121608353 @default.
• W4360607739 hasConceptScore W4360607739C126322002 @default.
• W4360607739 hasConceptScore W4360607739C143998085 @default.
• W4360607739 hasConceptScore W4360607739C2776235491 @default.
• W4360607739 hasConceptScore W4360607739C2779013556 @default.
• W4360607739 hasConceptScore W4360607739C2780192828 @default.
• W4360607739 hasConceptScore W4360607739C29456083 @default.
• W4360607739 hasConceptScore W4360607739C509974204 @default.
• W4360607739 hasConceptScore W4360607739C71924100 @default.
• W4360607739 hasIssue "Supplement 4" @default.
• W4360607739 hasLocation W43606077391 @default.
• W4360607739 hasOpenAccess W4360607739 @default.
• W4360607739 hasPrimaryLocation W43606077391 @default.
• W4360607739 hasRelatedWork W1980245127 @default.
• W4360607739 hasRelatedWork W2016249226 @default.
• W4360607739 hasRelatedWork W2098154216 @default.
• W4360607739 hasRelatedWork W2106003470 @default.
• W4360607739 hasRelatedWork W2212921542 @default.
• W4360607739 hasRelatedWork W2321033326 @default.
• W4360607739 hasRelatedWork W2433835599 @default.
• W4360607739 hasRelatedWork W3029905168 @default.
• W4360607739 hasRelatedWork W335723942 @default.
• W4360607739 hasRelatedWork W4220689252 @default.
• W4360607739 hasVolume "209" @default.
• W4360607739 isParatext "false" @default.
• W4360607739 isRetracted "false" @default.
• W4360607739 workType "article" @default.